tbuckley/cabot-search huggingface dataset:
Reversal of bleomycin-induced rat pulmonary fibrosis by a xenograft of human umbilical mesenchymal stem cells from Wharton's jelly
Authors: Kuo-An Chu, Shih-Yao Wang, Chang-Ching Yeh, Tz-Win Fu, Yu-Yi Fu, Tsui-Ling Ko, Mei-Miao Chiu, Tien-Hua Chen, Pei-Jiun Tsai, Yu-Show Fu
Journal: Theranostics (2019)

Pulmonary fibrosis (PF) is a progressive and irreversible condition with various causes, and no effective treatment has been found to rescue fibrotic lungs. Successful recovery from PF requires inhibiting inflammation, promoting collagen degradation and stimulating alveolar regeneration. Human umbilical mesenchymal stem cells (HUMSCs) not only regulate immune responses but also synthesize and release hyaluronan to improve lung regeneration. This study investigated the feasibility of HUMSC engraftment into rats with bleomycin (BLM)-induced PF to explore HUMSC therapeutic effects/outcomes. Methods: A unique BLM-induced left-lung-dominated PF animal model was established. Rats were transplanted with low-dose (5×106) or high-dose (2.5×107) HUMSCs on Day 21 after BLM injection. Combinations in co-culture of pulmonary macrophages, fibroblasts, HUMSCs treated with BLM and the same conditions on alveolar epithelia versus HUMSCs were evaluated. Results: Rats with high-dose HUMSC engraftment displayed significant recovery, including improved blood oxygen saturation levels and respiratory rates. High-dose HUMSC transplantation reversed alveolar injury, reduced cell infiltration and ameliorated collagen deposition. One month posttransplantation, HUMSCs in the rats' lungs remained viable and secreted cytokines without differentiating into alveolar or vascular epithelial cells. Moreover, HUMSCs decreased epithelial-mesenchymal transition in pulmonary inflammation, enhanced macrophage matrix-metallopeptidase-9 (MMP-9) expression for collagen degradation, and promoted toll-like receptor-4 (TLR-4) expression in the lung for alveolar regeneration. In coculture studies, HUMSCs elevated the MMP-9 level in pulmonary macrophages, released hyaluronan into the medium and stimulated the TLR-4 quantity in the alveolar epithelium. Principal Conclusions: Transplanted HUMSCs exhibit long-term viability in rat lungs and can effectively reverse rat PF.
TCT-660 Repeat Vascular Brachytherapy for Recurrent In-Stent Restenosis in Patients With Failed Intracoronary Radiation Therapy
Authors: Yuefeng Chen, Nauman Khalid, Evan Shlofmitz, Micaela Iantorno, Deepakraj Gajanana, Anees Musallam, Jaffar Khan, Toby Rogers, Hayder Hashim, Nelson Bernardo, Itsik Ben-Dor, Cheng Zhang, Rebecca Torguson, Lowell Satler, Ron Waksman
Journal: Journal of the American College of Cardiology (2019)
Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
Authors: Paul G Richardson, Joseph Mikhael, Saad Z Usmani, Noopur Raje, William Bensinger, Dheepak Kanagavel, Lei Gao, Samira Ziti-Ljajic, Kenneth C Anderson
Journal: Blood (2017)
The bracteatus pineapple genome and domestication of clonally propagated crops
Authors: Li-Yu Chen, Robert VanBuren, Margot Paris, Hongye Zhou, Xingtan Zhang, Ching Man Wai, Hansong Yan, Shuai Chen, Michael Alonge, Srividya Ramakrishnan, Zhenyang Liao, Juan Liu, Jishan Lin, Jingjing Yue, Mahpara Fatima, Zhicong Lin, Jisen Zhang, Lixian Huang, Hao Wang, Teh-Yang Hwa, Shu-Min Kao, Jae Young Choi, Anupma Sharma, Jian Song, Lulu Wang, Won C. Yim, John C. Cushman, Robert E. Paull, Tracie Matsumoto, Yuan Qin, Qingsong Wu, Jianping Wang, Qingyi Yu, Jun Wu, Shaoling Zhang, Peter Boches, Chih-Wei Tung, Ming-Li Wang, Geo Coppens d’Eeckenbrugge, Garth M. Sanewski, Michael D. Purugganan, Michael C. Schatz, Jeffrey L. Bennetzen, Christian Lexer, Ray Ming
Journal: Nature Genetics (2019)

Abstract Domestication of clonally propagated crops such as pineapple from South America was hypothesized to be a ‘one-step operation’. We sequenced the genome of Ananas comosus var. bracteatus CB5 and assembled 513 Mb into 25 chromosomes with 29,412 genes. Comparison of the genomes of CB5, F153 and MD2 elucidated the genomic basis of fiber production, color formation, sugar accumulation and fruit maturation. We also resequenced 89 Ananas genomes. Cultivars ‘Smooth Cayenne’ and ‘Queen’ exhibited ancient and recent admixture, while ‘Singapore Spanish’ supported a one-step operation of domestication. We identified 25 selective sweeps, including a strong sweep containing a pair of tandemly duplicated bromelain inhibitors. Four candidate genes for self-incompatibility were linked in F153, but were not functional in self-compatible CB5. Our findings support the coexistence of sexual recombination and a one-step operation in the domestication of clonally propagated crops. This work guides the exploration of sexual and asexual domestication trajectories in other clonally propagated crops.
TCT-651 Superior Crossability of Novel Cutting Balloon for the Preparation of Calcified Lesion -SUPERHERO Study-
Authors: Takayuki Ishihara, Osamu Iida, Mitsutoshi Asai, Kiyonori Nanto, Takashi Kanda, Takuya Tsujimura, Shota Okuno, Yasuhiro Matsuda, Yosuke Hata, Hiroyuki Uematsu, Toshiaki Mano
Journal: Journal of the American College of Cardiology (2019)
TCT-287 Impact of Eligibility Criteria on Clinical Outcomes of Firehawk and XIENCE Coronary Drug-Eluting Stent in an All-Comers Randomized Trial
Authors: Yuichi Saito, William Wijns, Andreas Baumbach, Bo Xu, Henning Kelbæk, Niels van Royen, Ming Zheng, Paul Knaapen, Ton Slagboom, Tom Johnson, Georgios Vlachojannis, Lene Holmvang, Luc Janssens, Andrzej Ochala, Salvatore Brugaletta, Richard Anderson, Harald Rittger, Sergio Berti, Emanuele Barbato, Gabor Toth, Luc Maillard, Christian Valina, Pawel Buszman, Holger Thiele, Alexandra Lansky
Journal: Journal of the American College of Cardiology (2019)
TCT-163 The Prothrombotic Transcriptomic Signature of Reticulated Platelets
Authors: Dario Bongiovani, Moritz von Scheidt, Gianluca Santamaria, Donato Santovito, Melissa Klug, Clelia Peano, Christian Weber, Gianluigi Condorelli, Karl-Ludwig Laugwitz, Isabell Bernlochner
Journal: Journal of the American College of Cardiology (2019)
TCT-501 Forging Partnerships for Constructing a Telemedicine-Guided, Nationwide STEMI Program for Mexico
Authors: Sameer Mehta, Roberto Botelho, Jamil Cade, Marco Perin, Mauricio Prudente, Ricardo Cavalcanti, Cesar Dusilek, Rodolfo Cardoso, Nabil Handam, Luis Ignacio Calderon, Marco Alcocer-Gamba, Juan Carlos Perez Alva, Manuel De Los Rios Ibarra, Alfredo Estrada, Alejandro Ricalde, Alejandra Frauenfelder, Daniel Vieira, Gladys Pinto, Lorena Pisana, Anibal Munguia, Samantha Quintero, Maria Marin, Isabella Vallenilla, Carlos Peña, Genesis Del Nogal
Journal: Journal of the American College of Cardiology (2019)
TCT-274 A Prospective Multicenter Study to Assess the Long-Term Safety and Efficacy of Sirolimus-Coated Balloon in Treatment of In-Stent Restenosis in Unselected Real-World Patients
Authors: Azeem Latib, Sameer Dani, Keyur Parikh, Prathrap Kumar, Ranjan Shetty, Jagdish Hiremath, Dinesh Shah
Journal: Journal of the American College of Cardiology (2019)
TCT-113 Adverse Events After Left Atrial Appendage Closure: Lessons Learned From the Manufacturer and User Facility Device Experience (MAUDE) Database.
Authors: Swaiman Singh, Alexis Okoh, Christoph Sossou, Joseph Heaton, Mayal Sandhu, Ritu Chakrabarti, Rameez Rao, Rajiv Tayal, Najam Wasty, Sergio Waxman
Journal: Journal of the American College of Cardiology (2019)
TCT-770 Outcomes After Endograft Facilitated Transcatheter Pulmonary Valve Replacement for Failed Repair: Surgical vs. Transcatheter Procedures
Authors: Norihiko Kamioka, John Lisko, Samuel Maidman, Dennis Kim, Anurag Sahu, Andy Dong, Subhadra Shashidharan, Maan Jokhadar, Fred Rodriguez, Wendy Book, Patrick Gleason, Peter Block, Vasilis Babaliaros
Journal: Journal of the American College of Cardiology (2019)
Alteration of Cardiac Performance and Serum B-Type Natriuretic Peptide Level in Healthy Aging
Authors: Yuriko Yoshida, Koki Nakanishi, Masao Daimon, Jumpei Ishiwata, Naoko Sawada, Megumi Hirokawa, Hidehiro Kaneko, Tomoko Nakao, Yoshiko Mizuno, Hiroyuki Morita, Marco R. Di Tullio, Shunichi Homma, Issei Komuro
Journal: Journal of the American College of Cardiology (2019)
The Universally Conserved Residues Are Not Universally Required for Stable Protein Expression or Functions of Cryptochromes
Authors: Huachun Liu, Tiantian Su, Wenjin He, Qin Wang, Chentao Lin
Journal: Molecular Biology and Evolution (2019)

Universally conserved residues (UCRs) are invariable amino acids evolutionarily conserved among members of a protein family across diverse kingdoms of life. UCRs are considered important for stability and/or function of protein families, but it has not been experimentally examined systematically. Cryptochromes are photoreceptors in plants or light-independent components of the circadian clocks in mammals. We experimentally analyzed 51 UCRs of Arabidopsis cryptochrome 2 (CRY2) that are universally conserved in eukaryotic cryptochromes from Arabidopsis to human. Surprisingly, we found that UCRs required for stable protein expression of CRY2 in plants are not similarly required for stable protein expression of human hCRY1 in human cells. Moreover, 74% of the stably expressed CRY2 proteins mutated in UCRs retained wild-type-like activities for at least one photoresponses analyzed. Our finding suggests that the evolutionary mechanisms underlying conservation of UCRs or that distinguish UCRs from non-UCRs determining the same functions of individual cryptochromes remain to be investigated.
TCT-391 10-Year Clinical Outcomes After Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease According to Lesion Location: Results From the MAIN-COMPARE Registry
Authors: Junho Hyun, Ju Hyeon Kim, Yeongjin Jeong, KyungJin Choe, Junghoon Lee, Sangwoo Park, Hanbit Park, Sang-Cheol Cho, Euihong Ko, Do-Yoon Kang, Pil Hyung Lee, Jung-Min Ahn, Duk-Woo Park, Seung-Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Authors: Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R. Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer, Klaus Baumann, Kris Jardon, Andrés Redondo, Richard G. Moore, Christof Vulsteke, Roisin E. O’Cearbhaill, Bente Lund, Floor Backes, Pilar Barretina-Ginesta, Ashley F. Haggerty, Maria J. Rubio-Pérez, Mark S. Shahin, Giorgia Mangili, William H. Bradley, Ilan Bruchim, Kaiming Sun, Izabela A. Malinowska, Yong Li, Divya Gupta, Bradley J. Monk
Journal: New England Journal of Medicine (2019)

Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients with recurrent ovarian cancer after platinum-based chemotherapy, regardless of the presence or absence of BRCA mutations. The efficacy of niraparib in patients with newly diagnosed advanced ovarian cancer after a response to first-line platinum-based chemotherapy is unknown.In this randomized, double-blind, phase 3 trial, we randomly assigned patients with newly diagnosed advanced ovarian cancer in a 2:1 ratio to receive niraparib or placebo once daily after a response to platinum-based chemotherapy. The primary end point was progression-free survival in patients who had tumors with homologous-recombination deficiency and in those in the overall population, as determined on hierarchical testing. A prespecified interim analysis for overall survival was conducted at the time of the primary analysis of progression-free survival.Of the 733 patients who underwent randomization, 373 (50.9%) had tumors with homologous-recombination deficiency. Among the patients in this category, the median progression-free survival was significantly longer in the niraparib group than in the placebo group (21.9 months vs. 10.4 months; hazard ratio for disease progression or death, 0.43; 95% confidence interval [CI], 0.31 to 0.59; P<0.001). In the overall population, the corresponding progression-free survival was 13.8 months and 8.2 months (hazard ratio, 0.62; 95% CI, 0.50 to 0.76; P<0.001). At the 24-month interim analysis, the rate of overall survival was 84% in the niraparib group and 77% in the placebo group (hazard ratio, 0.70; 95% CI, 0.44 to 1.11). The most common adverse events of grade 3 or higher were anemia (in 31.0% of the patients), thrombocytopenia (in 28.7%), and neutropenia (in 12.8%). No treatment-related deaths occurred.Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-free survival than those who received placebo, regardless of the presence or absence of homologous-recombination deficiency. (Funded by GlaxoSmithKline; PRIMA/ENGOT-OV26/GOG-3012 ClinicalTrials.gov number, NCT02655016.).
CAR T cell viability release testing and clinical outcomes: is there a lower limit?
Authors: Elise A. Chong, Bruce L. Levine, Stephan A. Grupp, Megan M. Davis, Don L. Siegel, Shannon L. Maude, Whitney L. Gladney, Noelle V. Frey, David L. Porter, Wei-Ting Hwang, Emeline R. Chong, Carl H. June, Stephen J. Schuster
Journal: Blood (2019)
Evaluation of cardiovascular risk in a lung cancer screening cohort
Authors: Mamta Ruparel, Samantha L Quaife, Jennifer L Dickson, Carolyn Horst, Stephen Burke, Magali Taylor, Asia Ahmed, Penny Shaw, May-Jan Soo, Arjun Nair, Anand Devaraj, Emma Louise O'Dowd, Angshu Bhowmik, Neal Navani, Karen Sennett, Stephen W Duffy, David R Baldwin, Reecha Sofat, Riyaz S Patel, Aroon Hingorani, Sam M Janes
Journal: Thorax (2019)

Introduction Lung cancer screening (LCS) by low-dose computed tomography (LDCT) offers an opportunity to impact both lung cancer and coronary heart disease mortality through detection of coronary artery calcification (CAC). Here, we explore the value of CAC and cardiovascular disease (CVD) risk assessment in LCS participants in the Lung Screen Uptake Trial (LSUT). Methods In this cross-sectional study, current and ex-smokers aged 60–75 were invited to a ‘lung health check’. Data collection included a CVD risk assessment enabling estimation of 10 year CVD risk using the QRISK2 score. Participants meeting the required lung cancer risk underwent an ungated, non-contrast LDCT. Descriptive data, bivariate associations and a multivariate analysis of predictors of statin use are presented. Results Of 1005 individuals enrolled, 680 were included in the final analysis. 421 (61.9%) had CAC present and in 49 (7.2%), this was heavy. 668 (98%) of participants had a QRISK2≥10% and QRISK2 was positively associated with increasing CAC grade (OR 4.29 (CI 0.93 to 19.88) for QRISK2=10%–20% and 12.29 (CI 2.68 to 56.1) for QRISK2≥20% respectively). Of those who qualified for statin primary prevention (QRISK2≥10%), 56.8% did not report a history of statin use. In the multivariate analysis statin use was associated with age, body mass index and history of hypertension and diabetes. Conclusions LCS offers an important opportunity for instituting CVD risk assessment in all LCS participants irrespective of the presence of LDCT-detected CAC. Further studies are needed to determine whether CAC could enhance uptake and adherence to primary preventative strategies.
The Use of the <i>International Classification of Diseases, Tenth Revision, Clinical Modification and Procedure Classification System</i> in Clinical and Health Services Research
Authors: Garth H. Utter, Oluseun O. Atolagbe, David T. Cooke
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
TCT-233 Mortality and In-Hospital Outcome of Patients With Chronic Total Occlusion Undergoing Percutaneous Coronary Intervention: Race-Based Trend Analysis From Nationwide Inpatient Sample
Authors: Sandipan Chakraborty, Dhrubajyoti Bandyopadhyay, Birendra Amgai, Neelkumar Patel, Aneeta Kumari, Soniya Koirala, Adrija Hajra, Manasvi Gupta, Raktim Ghosh, Eyal Herzog, Wilbert Aronow
Journal: Journal of the American College of Cardiology (2019)
TCT-76 Mid-Term Outcomes after Transcatheter Aortic Valve Replacement With a Mechanically-Expanded Versus Self-Expandable Valve: 3-Year Results From the REPRISE III Randomized Trial
Authors: David Rizik, Vivek Rajagopal, Tanvir Bajwa, Jeffrey Southard, Steven Yakubov, Donald Cutlip, Paul Teirstein, Leo Ihlberg, Dominic Allocco, Michael Reardon
Journal: Journal of the American College of Cardiology (2019)
TCT-286 Efficacy and Safety of the Newer Generation Zotarolimus-Eluting Stent in Routine Clinical Practice: Data From the IRIS-DES Registry
Authors: Ju Hyeon Kim, Sangwoo Park, Junho Hyun, Yeongjin Jeong, Junghoon Lee, Yujin Yang, KyungJin Choe, Hanbit Park, Sang-Cheol Cho, Euihong Ko, Do-Yoon Kang, Pil Hyung Lee, Jung-Min Ahn, Duk-Woo Park, Seung-Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2019)
TCT-104 Efficacy and Safety of the NovaCross Microcatheter for Chronic Total Occlusions: An Expanded Safety Study
Authors: Simon Walsh, Dariusz Dudek, Dimitri Karmpaliotis, William Nicholson, Margaret McEntegart, James Spratt, Barry Uretsky, Paul Knaapen, Mark Goodwin
Journal: Journal of the American College of Cardiology (2019)
TCT-740 Association Between Surgical Risk Profiles and Total Cost or Resource Utilization After Transcatheter Aortic Valve Replacement
Authors: Alexis Okoh, Nawar Al Obaidi, Mariam Selevany, Swaiman Singh, Christopher Pettit, Chunguang Chen, Bruce Haik, Marc Cohen, Leonard Lee, Mark Russo
Journal: Journal of the American College of Cardiology (2019)
TCT-419 Predictors of 5-Year Mortality After PCI: An Individual Patient-Data Pooled Analysis of 32,882 Patients From 21 Randomized Controlled Trials
Authors: Mayank Yadav, Patrick Serruys, Roxana Mehran, Pieter Smits, Clemens von Birgelen, Gary Mintz, Ajay Jayant Kirtane, Zixuan Zhang, Mahesh Madhavan, Bjorn Redfors, Martin Leon, Gregg Stone
Journal: Journal of the American College of Cardiology (2019)
TCT-84 Renal Denervation With Symplicity Spyral Catheter in the Global Symplicity Registry: Safety and Efficacy at 3 Years
Authors: Michael Böhm, Felix Mahfoud, Bryan Williams, Luis Ruilope, Krzysztof Narkiewicz, Markus Schlaich, Martin Fahy, Giuseppe Mancia
Journal: Journal of the American College of Cardiology (2019)
Outcome disparities in elder patients with colorectal cancer receiving definitive surgery: A nationwide population-based study in Taiwan.
Authors: Chia-Jen Liu, San-Chi Chen, Chueh-Chuan Yen, Hao Wei Teng, Ming-Huang Chen, Chun-Yu Liu, Ta-Chung Chao, Tzeon-Jye Chiou, Po-Min Chen, Jun-Huang Liu, Chung-Jen Teng
Journal: Journal of Clinical Oncology (2017)

e15119 Background: There are increasing numbers of elderly patients with colorectal cancer (CRC). With the advance of cancer treatment in recent years, more elderly CRC patients receive curative surgery and multidisciplinary cancer treatment. The purpose of this study is to identify the risk factors of mortality and to improve survival of these patients. Methods: We recruited newly diagnosed CRC patients between 2005 and 2012 from Taiwan's nationwide health insurance database. Patients without definitive surgery for CRC were excluded. CRC patients aged &lt; 65 years (non-elderly) were served as a reference group. The study cohort was followed until the end of 2013. Univariate and multivariate Cox proportional hazards models were applied to find the predictors of death among our study cohort. Results: During the 9-year study period, 10,818 (30.6%) died among 35,298 elderly CRC patients receiving definitive surgery, with a median follow-up period of 3.0 years. The median overall survival (OS) of the elderly patients was improved 1.4% per year (95% confidence interval [CI] 0.5–2.4%). Multivariate analysis showed that adjusted hazard ratios (HRs) for OS were 1.00, 1.23, 1.56, 2.15 in the patients aged 65–70, 70–75, 75–80, and ≥ 80 compared to those aged &lt; 65, respectively. The older patients had a higher probability of having ≥ 2 underlying comorbidities (71.4% vs. 31.4%) and without postoperative treatment (42.1% vs. 28.8%), which might be associated with the increase of mortality risk. Conclusions: This largest cohort study demonstrated an increasing risk of mortality in elderly CRC patients, especially those with ≥ 2 underlying comorbidities and those without postoperative treatment. [Table: see text]
Posttransplant Cyclophosphamide Promote Naïve-Subset Dominant B Cell Recovery Coordinated with Early Treg Expansion; Implication of Reduced Risk of Pathogenesis into Chronic Gvhd
Authors: Miki Iwamoto, Yusuke Meguri, Takumi Kondo, Hiroyuki Sugiura, Shuntaro Ikegawa, Yasuhisa Sando, Makoto Nakamura, Yoshinobu Maeda, Ken-Ichi Matsuoka
Journal: Blood (2018)
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib
Authors: Gary A. Ulaner, Cristina Saura, Sarina A. Piha-Paul, Ingrid Mayer, David Quinn, Komal Jhaveri, Ben Stone, Seta Shahin, Grace Mann, Melanie Dujka, Richard Bryce, Funda Meric-Bernstam, David B. Solit, David M. Hyman
Journal: Clinical Cancer Research (2019)

To determine whether FDG PET can expand eligibility in biomarker-selected clinical trials by providing a means to quantitate response in patients with non-assessable disease by RECIST.SUMMIT (NCT01953926) is a multicenter phase II "basket" trial of the Pan-HER kinase inhibitor, neratinib. Patients had advanced ERBB2 (HER2)-mutant solid tumors, ≥1 measurable lesion, preferably defined unidimensionally by RECIST v1.1, or alternatively metabolically by PET Response Criteria (PRC). The primary aim was to determine the proportion of additional breast cancer patients accrued using PRC who would have otherwise been ineligible based on RECIST criteria alone. The secondary aim was to determine the concordance of response versus non-response between RECIST and PRC.Eighty-one patients with HER2-mutant metastatic breast cancer were accrued; 77 were evaluable for response by RECIST and/or PRC. 63 (82%) were RECIST-evaluable and 14 (18%) were accrued using PRC alone. Bone-only disease (n = 11; 79%) was the most common reason for classification as non-measurable by RECIST. Twenty-nine patients were accrued and followed using both criteria, of which 25 (86%; 95% confidence interval, 68%-96%) were concordant for response versus non-response as defined by RECIST and PRC.PRC allowed patients with non-RECIST measurable disease access to therapy and facilitated more rapid accrual of patients to this trial of a rare biomarker. PRC and RECIST both provided methods of response assessment and were generally concordant. Thus, PRC was useful as a supplement to RECIST criteria. This provides a rationale for including FDG PET measurements in future clinical trials involving rare tumors or rare genomically defined subpopulations of more common cancers.